Short answer
Tyra Biosciences, Inc. (TYRA) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $400.0M gross proceeds from 9,079,000 shares and 9,078,529 pre-funded warrants.
Tyra Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $400.0M gross proceeds from 9,079,000 shares and 9,078,529 pre-funded warrants
- Underwritten offering priced at $22.03 per share, with underwriters purchasing at $20.7082
- Pre-funded warrants immediately exercisable at $0.001 and non-expiring, creating substantial potential dilution
- Beneficial ownership caps of 4.99%, 9.99% or 19.99% limit individual holder exercises
- Closing expected September 15, 2026, subject to customary conditions
Item EX-99.1 · Exhibit EX-99.1
- $400.0M gross equity offering priced at $22.03 per share, materially strengthening Tyra’s funding position
- 9,079,000 shares plus pre-funded warrants for 9,078,529 shares, creating substantial potential dilution
- Proceeds targeted toward dabogratinib development in LG-UTUC, IR NMIBC and achondroplasia
- Additional funding supports preclinical discovery, working capital and general corporate purposes
- Closing expected September 15, 2026, subject to customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tyra Biosciences, Inc. 8-K filings
Get the next TYRA 8-K as it lands
Follow TYRA for push alerts, or ask the research agent what this filing means.